8-K: Kairos Pharma Announces Dual Listing on Upstream Exchange to Expand Global Investor Access

Kairos Pharma will dual list its shares on the Upstream exchange, a global securities trading app, starting November 26, 2024, to broaden its investor base and enhance liquidity.

Summary

• Kairos Pharma, a Delaware corporation, has announced its approval for a dual listing on Upstream, a global securities trading app.
• Trading on Upstream will commence on November 26, 2024, at 10:00 a.m. ET under the ticker symbol KAPA.
• The dual listing aims to provide Kairos Pharma with access to a global investor base outside the U.S., enhancing liquidity and price discovery.
• Upstream is a MERJ Exchange market that offers real-time trading and settlement with a transparent order book.
• Kairos Pharma is focused on oncology therapeutics, with its lead candidate, ENV105, currently in Phase 2 clinical trials for castrate resistant prostate cancer and Phase 1 trials for lung cancer.
• The company believes the dual listing will support its goal of building shareholder value as it advances its therapeutics through clinical testing and commercialization.

Sentiment

Score: 7

Explanation: The document is positive due to the dual listing announcement, which is expected to increase investor access and liquidity. However, the presence of forward-looking statements and associated risks temper the overall sentiment.

Positives

• The dual listing on Upstream provides access to a global investor base, potentially increasing demand for the company's stock.
• Enhanced liquidity and price discovery are expected benefits of the dual listing.
• Upstream's platform offers real-time trading and settlement, which can be attractive to investors.
• The company's lead drug, ENV105, is in clinical trials, indicating progress in its therapeutic development.

Negatives

• U.S. persons are restricted from trading on the Upstream platform.
• The document contains forward-looking statements, which are subject to risks and uncertainties.
• The company acknowledges that actual results may differ materially from forward-looking statements.

Risks

• The company's success depends on the outcome of its clinical trials, which are subject to inherent risks and uncertainties.
• There is no guarantee that the dual listing will result in increased liquidity or a higher stock price.
• The company's forward-looking statements are based on current expectations and may not materialize.
• The company is subject to ongoing corporate obligations including disclosure, filings, and notification requirements.

Future Outlook

The company anticipates that the dual listing will support its goal of building shareholder value as it continues to expand its lead drug and advance its therapeutics through clinical testing and commercialization. However, the company cautions that forward-looking statements are subject to risks and uncertainties.

Management Comments

• Dr. John Yu, CEO of Kairos Pharma, stated that building shareholder value is an ongoing goal of Kairos.
• He believes a dual listing on Upstream's next generation market greatly supports this goal.

Industry Context

This announcement reflects a trend of companies seeking to expand their investor base by listing on international exchanges. The move to a digital trading platform like Upstream also aligns with the increasing adoption of technology in financial markets.

Comparison to Industry Standards

• Dual listings are a common strategy for companies seeking to increase their visibility and access to capital, similar to other biotech companies that have listed on multiple exchanges to attract a broader range of investors.
• The use of a digital trading platform like Upstream is a relatively new approach, but it aligns with the trend of increasing adoption of technology in financial markets, similar to other fintech platforms that are disrupting traditional trading methods.
• The company's focus on oncology therapeutics and clinical trials is consistent with the activities of other biotech companies in the sector, such as those developing novel cancer treatments.

Stakeholder Impact

• Shareholders may benefit from increased liquidity and potential price appreciation.
• The dual listing provides an opportunity for global investors to invest in the company.
• The company's employees may benefit from the company's growth and success.

Next Steps

• Trading on Upstream will commence on November 26, 2024.
• The company will continue to advance its clinical trials for ENV105.

Key Dates

Keywords

dual listing, Upstream, global securities trading, KAPA, Kairos Pharma, ENV105, oncology therapeutics, clinical trials, investor base, liquidity